Jazz Pharmaceuticals (JAZZ) Stock Price, Quote, News & History | Benzinga

Jazz Pharmaceuticals PLC (JAZZ) Stock Price, Quote, News & History

JAZZNASDAQ

Trade with Public

Trade with Public

$202.72

-0.30-0.15%

At close: May 1, 5:00 PM EST

$202.72

N/A

After Hours: May 1, 4:00 PM EST

Earnings: Q1 2026 earnings tomorrow on Tue May 5th after the market close

Conference Call: Conference call scheduled tomorrow at 4:30 PM

Click to view the webcast

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

$204.50

Close

$202.72

Volume / Avg.

572.39K / 943.94K

Day Range

$201.75 - $204.99

52 Wk Range

97.50 - 207.48

Market Cap

$12.72B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

9.61%

Days to Cover

5.97

Recent Jazz Pharmaceuticals PLC News

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.

Vandana Singh

Alphabet, Exact Sciences, And Regeneron Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 17-Nov. 21): Are the Others in Your Portfolio?

Discover last week's top 10 large-cap stock gainers, why they rallied, and what catalysts drove Alphabet, Exact Sciences, Regeneron higher.

Nabaparna Bhattacharya

Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).

Evette Mitkov

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.36B

Investing Cash Flow (TTM)

-1.51B

Financing Cash Flow (TTM)

-873.38M

Free Cash Flow (TTM)

1.15B

Capital Expenditure (TTM)

-209.75M

Net Change in Cash (TTM)

-1.03B

Analyst Trends and Forecast

2

Jan

5

Feb

1

Mar

2

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$15.70B

PE Ratio (TTM)

-

PE Ratio (FWD)

8.61

PEG Ratio (TTM)

0.66

PS Ratio (TTM)

2.90

PB Ratio (TTM)

2.95

Earnings Yield % (TTM)

-2.88%

Earnings Yield % (FWD)

11.62%

EV / EBITDA (TTM)

59.66

Price / EBITDA (TTM)

46.99

Price / Free Cash Flow (TTM)

10.80

Book Value / Share

$68.83

Company Debt

Total Debt

$5.36B

LT Debt

$4.33B

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-$781.00M

Total Cash

$1.39B

Debt to Equity

1.26

Issuance of Debt (TTM)

-$781.00M

Repayment of Debt (TTM)

-$781.00M

Key Statistics

Open

$204.50

Close

$202.72

Volume / Avg.

572.39K / 943.94K

Day Range

$201.75 - $204.99

52 Wk Range

97.50 - 207.48

Market Cap

$12.72B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

9.61%

Days to Cover

5.97

About

Sector

Health Care

Industry

Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Jazz Pharmaceuticals (JAZZ) stock?

A

You can purchase shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Jazz Pharmaceuticals (JAZZ) competitors?

A

Other companies in Jazz Pharmaceuticals’s space includes: Novo Nordisk AS (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and Terns Pharmaceuticals Inc (NASDAQ:TERN).

Q

What is the forecast, or price target, for Jazz Pharmaceuticals (JAZZ) stock?

A

Jazz Pharmaceuticals has a consensus price target of $213.40.

Q

What is the current price for Jazz Pharmaceuticals (JAZZ)?

A

The stock price for Jazz Pharmaceuticals (NASDAQ: JAZZ) is $202.72 last updated May 1, 2026 at 4:00 PM EDT.

Q

Does Jazz Pharmaceuticals (JAZZ) pay a dividend?

A

There are no upcoming dividends for Jazz Pharmaceuticals.

Q

When is Jazz Pharmaceuticals (NASDAQ:JAZZ) reporting earnings?

A

Jazz Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Jazz Pharmaceuticals (JAZZ) going to split?

A

There is no upcoming split for Jazz Pharmaceuticals.

Q

What sector and industry does Jazz Pharmaceuticals (JAZZ) operate in?

A

Jazz Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Novo Nordisk AS

Johnson & Johnson

Terns Pharmaceuticals Inc

Axsome Therapeutics Inc